Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.
Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, Connolly C, Fathi AT, Foster J, Macrae M, McAfee SL, McGregor K, Narayan R, Ramos AY, Som TT, Vartanian M, Friedman RS, Benhadji KA, Hobbs GS.
Kasbekar M, et al. Among authors: chen yb.
Blood Adv. 2020 Jul 14;4(13):3136-3140. doi: 10.1182/bloodadvances.2020002308.
Blood Adv. 2020.
PMID: 32649766
Free PMC article.